Clinical trial

Safety and Efficacy of Specific Immunotherapy With an Aluminium…

NCT00263627 · Allergopharma GmbH & Co. KG, Industry · Completed

Key facts

NCT number NCT00263627
Title Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
Official title A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
Lead sponsor Allergopharma GmbH & Co. KG, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Pollen Allergy
Intervention type Biological, Other
Interventions Birch pollen allergoid, Placebo
Enrollment 253
Start date Jun 1, 2005
Primary completion Jun 1, 2007
Completion Mar 1, 2010
First posted Dec 9, 2005
Last update posted Jul 3, 2014
Countries Germany

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies